Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer
A Prospective Study on the Efficacy and Safety of CD8+NKG2D+ AKT cell immunotherapy to the pancreatic cancer patients treated with adjuvant chemotherapy.
Pancreatic Ductal Adenocarcinoma
BIOLOGICAL: CD8+NKG2D+ AKT Cell|DRUG: Gemcitabine
Disease-free survival, 1 year
Overall Survival, 3 years|immune indices, 1 year|Quality of life, 3 years
A Prospective Study on the Efficacy and Safety of CD8+NKG2D+ AKT cell immunotherapy to the pancreatic cancer patients treated with adjuvant chemotherapy.